Deals In Depth: July 2019
Executive Summary
Gilead continued its R&D relationship with Galapagos in a new, nearly $10bn alliance. Exact Sciences and Genomic Health merged in a $2.8bn agreement creating a leading global molecular diagnostics company. Pharma financing was down while device funding increased thanks to a strong showing in the debt category, including ResMed's $498m offering.
You may also be interested in...
The Biopharma A List: Taking The Pulse Of Newco Creation
On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.
CGT Development Is Booming, But Manufacturing Workforce Must Keep Up
Due to the unprecedented growth in the development of cell and gene therapies over the past decade, there is now high demand for certain workforce roles, especially in highly specialized areas and entry-level manufacturing positions.
RNA Medicines: Advancements Leading To Investments
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.